Proglumide shows potential in this current study by improving hepatic histology and decreasing fibrosis in mice with NASH through several pathways including inhibition of the CCK receptor, serving as a partial agonist at the FXR, and rendering the gut microbiome less hepatotoxic. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.